Related Experiment Video
Updated: Nov 3, 2025
09:58
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
14.0K
AR Splicing Variants and Resistance to AR Targeting Agents
Mayuko Kanayama1, Changxue Lu1, Jun Luo1,2
1Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Cancers
|June 2, 2021
Summary
Androgen receptor splice variants (AR-Vs), particularly AR-V7, are crucial in prostate cancer progression and treatment resistance. Understanding AR-Vs aids in developing better biomarkers and therapies for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer treatment advances necessitate optimal biomarkers for treatment efficacy.
- Androgen receptor (AR) signaling is a primary target, with resistance often involving AR aberrations.
- Androgen receptor splice variants (AR-Vs), especially AR-V7, are implicated in castration-resistant prostate cancer (CRPC).
Purpose of the Study:
- To review the molecular mechanisms of AR-V generation, regulation, and function.
- To discuss the clinical significance of AR-Vs in various human specimens.
- To explore the potential of AR-Vs as prognostic and predictive biomarkers and therapeutic targets.
Main Methods:
- Review of preclinical and clinical studies on AR-Vs.
- Analysis of molecular mechanisms of AR-V generation and function.
- Evaluation of clinical utility of AR-V detection in human specimens.
Main Results:
- AR-Vs, including AR-V7, arise from aberrations in AR signaling.
- AR-Vs play a significant role in the development of treatment resistance in prostate cancer.
- AR-V7 shows potential as a prognostic and predictive biomarker in CRPC.
Conclusions:
- AR-Vs are critical mediators of resistance to AR-targeted therapies in prostate cancer.
- Further validation of AR-Vs in diverse clinical settings is essential.
- AR-Vs represent promising targets for novel therapeutic strategies in CRPC.
Related Concept Videos
01:32RNA Splicing
58.2K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
58.2K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:18Alternative RNA Splicing
22.9K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
22.9K
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:53Conservative Site-specific Recombination and Phase Variation
6.3K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.3K